Watch PALI. Know when insiders buy.
One email the day a filing lands. Free.
PALI
PALISADE BIO, INC.
1.57
−0.03 −1.87%
USD · close Sep 24
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
70
PASS · shorts 70
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $273.6MP/E 2.6DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$31.9MNET CASH $125.1M52W 0.77 – 2.80SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $500K | — | — | −$11.7M | −$10.6M | — | -0.05 | −$7.6M | — | — | Aug 10 |
| Q1 2026 · Mar 31 | — | — | — | −$10.7M | −$9.6M | — | -0.05 | −$3.9M | — | — | May 12 |
| Q4 2025 · Dec 31derived | — | — | — | −$10M | −$8.9M | — | 1.08 | −$3.1M | — | — | Mar 20 |
| Q3 2025 · Sep 30 | — | — | — | −$2.9M | −$2.9M | — | -0.38 | −$3.6M | — | — | Nov 10 |
| Q2 2025 · Jun 30 | $0 | — | — | −$2.8M | −$2.8M | — | -0.58 | −$1.8M | — | — | Aug 10 |
| Q1 2025 · Mar 31 | — | — | — | −$2.3M | −$2.2M | — | -0.47 | −$2.3M | — | — | May 12 |
| Q4 2024 · Dec 31derived | $0 | — | — | −$3.4M | −$3.3M | — | -0.69 | −$2.4M | $0 | −$2.4M | Mar 20 |
| Q3 2024 · Sep 30 | $0 | — | — | −$3.6M | −$3.5M | — | -2.32 | −$3.1M | $0 | −$3.1M | Nov 10 |
| Q2 2024 · Jun 30 | $0 | — | — | −$4.2M | −$4.1M | — | -3.32 | −$3.5M | — | — | Aug 11 |
| Q1 2024 · Mar 31 | $0 | — | — | −$3.7M | −$3.5M | — | -4.59 | −$3.2M | — | — | May 12 |
| Q4 2023 · Dec 31 | $0 | — | — | −$3.2M | −$3M | — | -3.77 | −$2.7M | $0 | −$2.7M | Mar 24 |
| Q3 2023 · Sep 30 | $0 | — | — | −$3.8M | −$3.6M | — | -7.38 | −$2.7M | $0 | −$2.7M | Nov 12 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$18.1M | −$16.8M | — | -0.30 | −$10.8M | — | — | — | — |
| FY2024 · to Dec 31 | $0 | — | −$14.9M | −$14.4M | — | -10.19 | −$12.2M | $0 | −$12.2M | — | — |
| FY2023 · to Dec 31 | $250K | — | −$13.1M | −$12.3M | -4920.0% | -27.01 | −$11.1M | $4K | −$11.1M | — | — |
| FY2022 · to Dec 31 | $0 | — | −$15.7M | −$14.3M | — | -16.53 | −$13.4M | $10K | −$13.4M | — | — |
| FY2021 · to Dec 31 | — | — | −$41.9M | −$26.6M | — | -169.74 | −$14.8M | $0 | −$14.8M | — | — |
| FY2020 · to Dec 31 | — | — | −$9.3M | −$10.3M | — | -3.72 | −$4.8M | $6K | −$4.8M | — | — |
Every number comes from PALISADE BIO, INC.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.